Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384

References

• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987 - 96; http://dx.doi.org/10.1056/NEJMoa043330; PMID: 15758009
   PubMed Web of Science ®Google Scholar
• Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008; 26:3015 - 24; http://dx.doi.org/10.1200/JCO.2007.15.7164; PMID: 18565887
   PubMed Web of Science ®Google Scholar
• Rich JN, Rasheed BK, Yan H. EGFR mutations and sensitivity to gefitinib. The New England journal of medicine. 2004; 351:1260 1
   Google Scholar
• Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67:11924 - 32; http://dx.doi.org/10.1158/0008-5472.CAN-07-1885; PMID: 18089823
   PubMed Web of Science ®Google Scholar
• Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson JM, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008; 7:1880 - 9; http://dx.doi.org/10.1158/1535-7163.MCT-07-2232; PMID: 18606718
   PubMed Web of Science ®Google Scholar
• Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009; 69:3256 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-08-4055; PMID: 19351834
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012 - 24; http://dx.doi.org/10.1056/NEJMoa051918; PMID: 16282176
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039 - 43; http://dx.doi.org/10.1126/science.1141478; PMID: 17463250
   PubMed Web of Science ®Google Scholar
• Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal 2009; 2:ra4; http://dx.doi.org/10.1126/scisignal.2000014; PMID: 19176518
   PubMedGoogle Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061 - 8; http://dx.doi.org/10.1038/nature07385; PMID: 18772890
   PubMed Web of Science ®Google Scholar
• Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9:469 - 79; http://dx.doi.org/10.1111/j.1750-3639.1999.tb00536.x; PMID: 10416987
   PubMed Web of Science ®Google Scholar
• Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 1990; 87:8602 - 6; http://dx.doi.org/10.1073/pnas.87.21.8602; PMID: 2236070
   PubMed Web of Science ®Google Scholar
• Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318:287 - 90; http://dx.doi.org/10.1126/science.1142946; PMID: 17872411
   PubMed Web of Science ®Google Scholar
• Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, Chen Z, dos Santos O, Ayral-Kaloustian S, Venkatesan A, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res 2011; 17:3193 - 203; http://dx.doi.org/10.1158/1078-0432.CCR-10-1694; PMID: 21325073
   PubMed Web of Science ®Google Scholar
• Wakimoto H, Mohapatra G, Kanai R, Curry WT Jr., Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis DN, et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol 2012; 14:132 - 44; http://dx.doi.org/10.1093/neuonc/nor195; PMID: 22067563
   PubMed Web of Science ®Google Scholar
• Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 2010; 107:6459 - 64; http://dx.doi.org/10.1073/pnas.0911188107; PMID: 20308550
   PubMed Web of Science ®Google Scholar
• Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004; 10:3216 - 24; http://dx.doi.org/10.1158/1078-0432.CCR-03-0521; PMID: 15131063
   PubMed Web of Science ®Google Scholar
• Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 2007; 104:12867 - 72; http://dx.doi.org/10.1073/pnas.0705158104; PMID: 17646646
   PubMed Web of Science ®Google Scholar
• Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 2013; 154:1269 - 84; http://dx.doi.org/10.1016/j.cell.2013.08.015; PMID: 24034250
   PubMed Web of Science ®Google Scholar
• Botti J, Djavaheri-Mergny M, Pilatte Y, Codogno P. Autophagy signaling and the cogwheels of cancer. Autophagy 2006; 2:67 - 73; PMID: 16874041
   PubMed Web of Science ®Google Scholar
• Wang RC, Wei Y, An Z, Zou Z, Xiao G, Bhagat G, White M, Reichelt J, Levine B. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science 2012; 338:956 - 9; http://dx.doi.org/10.1126/science.1225967; PMID: 23112296
   PubMed Web of Science ®Google Scholar
• Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 2011; 71:154 - 63; http://dx.doi.org/10.1158/0008-5472.CAN-10-1601; PMID: 21084267
   PubMed Web of Science ®Google Scholar
• Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr., Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009; 69:3472 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-08-3886; PMID: 19351838
   PubMed Web of Science ®Google Scholar
• Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci 2008; 28:4406 - 13; http://dx.doi.org/10.1523/JNEUROSCI.0296-08.2008; PMID: 18434519
   PubMed Web of Science ®Google Scholar
• Meléndez B, García-Claver A, Ruano Y, Campos-Martín Y, Rodríguez de Lope A, Pérez-Magán E, Mur P, Torres S, Lorente M, Velasco G, Mollejo M. Copy Number Alterations in Glioma Cell Lines. In: Ghosh A, ed. Glioma - Exploring Its Biology and Practical Relevance. Rijeka Croatia: InTech; 2011.
   Google Scholar